See more : Gulshan Polyols Limited (GULPOLY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Neptune Wellness Solutions Inc. (NEPTF) Income Statement Analysis – Financial Results
- Eguana Technologies Inc. (EGTYF) Income Statement Analysis – Financial Results
- Triton Valves Limited (TRITONV.BO) Income Statement Analysis – Financial Results
- Roboserver Systems Corp. (RBSY) Income Statement Analysis – Financial Results
- ElringKlinger AG (ZIL2.DE) Income Statement Analysis – Financial Results
Abbott Laboratories (ABT)
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B | 10.01B | 9.16B | 8.41B | 7.85B | 6.88B | 6.16B | 5.38B | 4.94B | 4.39B | 3.81B | 3.36B |
| Cost of Revenue | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.34B | 9.02B | 8.75B | 9.22B | 10.04B | 15.12B | 15.54B | 14.67B | 13.21B | 12.61B | 11.42B | 9.82B | 10.64B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B | 4.33B | 3.99B | 3.68B | 3.08B | 2.76B | 2.55B | 2.25B | 2.08B | 1.86B | 1.67B | 1.54B |
| Gross Profit | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 15.05B | 11.83B | 11.66B | 11.03B | 11.81B | 24.75B | 23.31B | 20.50B | 17.56B | 16.92B | 14.49B | 12.66B | 11.70B | 10.80B | 10.21B | 9.18B | 8.54B | 7.51B | 7.20B | 7.08B | 6.84B | 6.28B | 5.69B | 5.16B | 4.72B | 4.77B | 4.12B | 3.60B | 3.13B | 2.85B | 2.53B | 2.14B | 1.82B |
| Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.96% | 56.73% | 57.13% | 54.47% | 54.05% | 62.08% | 60.00% | 58.30% | 57.06% | 57.29% | 55.92% | 56.33% | 52.36% | 54.86% | 51.86% | 51.90% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% | 56.79% | 56.38% | 56.18% | 60.81% | 59.85% | 58.53% | 58.19% | 57.82% | 57.65% | 56.17% | 54.19% |
| Research & Development | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.24B | 1.42B | 1.41B | 1.35B | 1.45B | 4.32B | 4.80B | 3.73B | 2.74B | 2.69B | 2.51B | 2.26B | 1.82B | 1.70B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.30B | 1.20B | 1.07B | 963.52M | 880.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -495.00K | -817.00K | -324.00K | 96.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Other Expenses | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 139.00M | 1.25B | -945.00M | 281.00M | -14.00M | 32.00M | 34.00M | -119.00M | 62.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -138.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70.00M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| Operating Expenses | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.33B | 8.64B | 8.79B | 8.43B | 9.18B | 16.38B | 17.56B | 14.10B | 11.15B | 11.12B | 9.91B | 8.60B | 7.32B | 6.62B | 6.78B | 5.54B | 5.31B | 4.11B | 4.05B | 3.97B | 3.99B | 3.66B | 3.30B | 3.02B | 2.80B | 3.25B | 2.56B | 2.20B | 1.91B | 1.75B | 1.52B | 1.26B | 1.08B |
| Cost & Expenses | 33.63B | 35.29B | 34.65B | 29.25B | 27.37B | 26.93B | 25.66B | 17.67B | 17.54B | 17.65B | 19.22B | 31.50B | 33.10B | 28.77B | 24.36B | 23.74B | 21.34B | 18.42B | 17.96B | 15.50B | 16.26B | 14.05B | 13.06B | 10.35B | 10.03B | 9.36B | 9.03B | 8.40B | 7.63B | 7.01B | 6.48B | 6.33B | 5.32B | 4.75B | 4.16B | 3.84B | 3.38B | 2.93B | 2.62B |
| Interest Income | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M | 105.00M | 77.00M | 67.00M | 79.23M | 85.20M | 105.45M | 137.78M | 201.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 637.00M | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M | 780.00M | 332.00M | 58.00M | 73.00M | 90.00M | 513.00M | 530.14M | 553.14M | 382.00M | 528.47M | 593.14M | 292.35M | 153.66M | 149.09M | 146.12M | 205.22M | 234.76B | 23.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 601.00M | 555.00M | 791.00M | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M | 566.42M | 510.50M | 484.08M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| EBITDA | 10.61B | 12.38B | 12.74B | 8.79B | 7.77B | 7.12B | 6.13B | 3.07B | 4.83B | 4.22B | 3.45B | 3.50B | 9.26B | 9.14B | 9.49B | 8.22B | 6.43B | 4.25B | 6.22B | 5.61B | 4.20B | 4.30B | 4.39B | 3.40B | 3.98B | 3.90B | 3.56B | 3.30B | 2.95B | 2.65B | 2.41B | 1.95B | 1.94B | 1.76B | 1.53B | 1.37B | 1.25B | 1.08B | 892.90M |
| EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% | 19.51% | 18.08% | 13.38% | 18.37% | 15.51% | 15.80% | 21.08% | 15.08% | 19.30% | 20.82% | 21.20% | 25.41% | 33.72% | 23.92% | 27.28% | 21.54% | 25.87% | 33.77% | 26.56% | 27.68% | 29.46% | 28.54% | 29.05% | 29.16% | 28.61% | 27.38% | 21.50% | 27.41% | 28.02% | 27.53% | 27.03% | 28.27% | 27.62% | 24.92% |
| Operating Income | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.73B | 3.19B | 2.87B | 2.60B | 2.63B | 8.09B | 5.75B | 6.09B | 6.24B | 5.69B | 4.58B | 2.04B | 4.36B | 3.90B | 3.32B | 3.53B | 1.89B | 3.40B | 3.15B | 3.12B | 2.85B | 2.62B | 2.38B | 2.14B | 1.92B | 1.53B | 1.56B | 1.41B | 1.22B | 1.10B | 1.01B | 878.60M | 737.10M |
| Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 6.30% | 15.27% | 14.05% | 12.84% | 12.03% | 20.28% | 14.81% | 17.31% | 20.27% | 19.28% | 17.67% | 9.09% | 19.53% | 19.81% | 16.88% | 19.96% | 11.63% | 24.74% | 23.90% | 24.99% | 23.99% | 23.76% | 23.80% | 23.42% | 22.88% | 19.43% | 22.64% | 22.83% | 22.70% | 22.32% | 22.92% | 23.07% | 21.94% |
| Total Other Income/Expenses | 186.00M | -56.00M | -214.00M | -389.00M | -455.00M | -777.00M | 667.00M | -1.61B | 316.00M | -81.00M | -92.00M | -1.22B | -553.36M | -374.75M | 958.03M | 162.45M | -108.90M | 234.15M | 257.65M | 227.28M | 411.89M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M | 12.42M | 22.48M | 19.26M | 212.80M | -12.80M | -55.30M | -27.00M | -46.60M | -68.50M | -59.90M | -42.60M |
| Income Before Tax | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.20B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.40B | 3.24B | 2.95B | 2.67B | 2.40B | 2.17B | 1.94B | 1.74B | 1.54B | 1.35B | 1.19B | 1.06B | 937.20M | 818.70M | 694.50M |
| Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.40% | 8.15% | 6.78% | 15.60% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% | 23.92% | 23.66% | 23.11% | 22.14% | 22.46% | 21.93% | 22.20% | 21.38% | 21.36% | 21.50% | 20.67% |
| Income Tax Expense | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M | 577.00M | 797.00M | 138.00M | 300.00M | 470.00M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M | 706.62M | 650.01M | 544.10M | 499.70M | 455.50M | 385.00M | 334.40M | 303.40M | 304.60M | 278.20M | 229.20M |
| Net Income | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B | 1.69B | 1.52B | 1.40B | 1.24B | 1.09B | 965.80M | 859.80M | 752.00M | 632.60M | 540.50M | 465.30M |
| Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.10% | 16.44% | 13.99% | 15.80% | 9.52% | 20.27% | 18.56% | 18.71% | 17.50% | 17.09% | 16.87% | 16.56% | 16.64% | 15.78% | 15.83% | 15.68% | 15.98% | 15.23% | 14.42% | 14.20% | 13.85% |
| EPS | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| EPS Diluted | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| Weighted Avg Shares Out | 1.73B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
| Weighted Avg Shares Out (Dil) | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Levi & Korsinsky, LLP Investigates Abbott Laboratories Employees Credit Union ("ALECU") Data Breach
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Abbott Laboratories Employees Credit Union ("ALECU")recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security of...
The lawsuits against Abbott 'really steam me', says Jim Cramer
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Jim Cramer takes a closer looks at the litigation facing Abbott and what it means for the company
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Abbott Laboratories Employees Credit Union ("ALECU") Data Breach - Levi & Korsinsky, LLP Launches Investigation
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the...
Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win
Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease.
Abbott shares rise after securing first win in premature infant formula trial
Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.
Abbott Labs and Reckitt Benckiser shares surge on court's baby formula ruling
A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC
Abbott, Reckitt cleared of liability in latest preterm formula case
Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit accusing them of failing to warn of their premature baby formulas' risks, a victory for the...
Levi & Korsinsky, LLP Announces Investigation Abbott Laboratories Employees Credit Union (“ALECU”)
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security...
Source: https://incomestatements.info
Category: Stock Reports